Regeneron Pharmaceuticals (REGN) announced on Tuesday that the European Commission approved a more convenient dosing regimen for its cancer therapy, Libtayo, that will cut patients’ clinic visits and potentially halve their infusion times.
The decision greenlights a higher 700 mg